Vanguard Asset Management
RLAY icon

Vanguard Asset Management’s Relay Therapeutics RLAY Stock Holding History

Vanguard Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Hold
82,300
– – ﹤0.01% 1678
2026
Q1 		$819K Buy
+82,300
New +$736K ﹤0.01% 1880

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Vanguard Asset Management's RLAY Position: Q2 2026 in Review

Vanguard Asset Management held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 82,300 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Vanguard Asset Management first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Vanguard Asset Management held 82,300 shares of Relay Therapeutics worth $1.54M as of Q2 2026.
  • Vanguard Asset Management left its Relay Therapeutics share count unchanged in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1678 holding.
  • Vanguard Asset Management first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.